Supervisory Board's opinion on the recommendation of the Company's Management Board regarding the allocation of 2024 profit

Date: 23 April 2025

Subject: Supervisory Board’s opinion on the recommendation of the Company’s Management Board regarding the allocation of 2024 profit

Legal basis: Article 17(1) of MAR – Inside information

Text of the report:

Further to Current Report No. 14/2025 of 22 April 2025 on the recommendation of the Management Board of Diagnostyka S.A. (the “Company” or the “Issuer”) regarding the allocation of profit for 2024, the Management Board announces that the Supervisory Board, at its meeting held on 23 April 2025, endorsed the Management Board’s recommendation of the following allocation of the Company’s 2024 profit of PLN 198,207,885.91:

• PLN 111,734,015.00 to be distributed as dividend of PLN 3.31 per share;
• the balance of PLN 86,473,870.91 to be transferred to the Company’s statutory reserve funds.

The dividend payout ratio is 50.03% of the amount disclosed in the Group’s financial statements under net profit attributable to owners of the parent, based on the Group’s preliminary estimates.

The Company’s governing body competent to resolve on the allocation of profit, including dividend payment, is the General Meeting.

The Company further announces that the final financial results for 2024 will be provided in the separate and consolidated full-year reports, scheduled for publication on 24 April 2025.

Specific legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/82/EC (OJ L 173) (“MAR”).

For the Company:

Paweł Chytła – Vice President of the Management Board

Marta Rogalska-Kupiec – Vice President of the Management Board